COVID-19: Get Vaccinated. Get Tested. Visitor Guidelines. Please use ER for Emergency Issues only.


  • A151216 Adjuvant Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
  • A081801 Integration of Immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO
  • E4512 Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • A171901 Older NSCLC patients (>/= 70 years of age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologists/patients choice)
  • EA5163 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
  • EA5181 Randomized Phase III trial of MEDI4736 (Durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC
  • EA5182 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
  • EA5191 A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Vs. Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
  • SWOG S1929 Phase II Randomized Study of Maintenance Atezolizumab Vs. Atezolizumab in Combination with Talazoparib in patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
  • SWOG S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC 783608) + SBRT vs. SBRT alone in High Risk, Early Stage NSCLC